MTCR News and Press, Metacrine Inc. From 08/12/21

Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter of 2021 Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes on track to be reported in the fourth...

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive of...

Shares of Metacrine Inc. (NASDAQ:MTCR) traded at a new 52-week low today of $3.07. This new low was reached on above average trading volume as 326,000 shares traded hands, while the average 30-day volume is approximately 188,000 shares. Metacrine Inc. (NASDAQ:MTCR) has potential upside o...

SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present new preclinical data at the European Crohn&#...

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present data at the European Association for the Stu...

Rasi Bhadramani/iStock via Getty Images H.C. Wainwright has initiated the coverage of Metacrine ([[MTCR]] +4.6%) with a buy rating. The firm has given a price target of $15.00 per share for the clinical-stage biopharma company to indicate a premium of ~262.3% to the last close. The analyst Ed...

Enochian Biosciences (ENOB) +143% on FDA acceptance of pre-IND request for potential HIV cure.MediaCo Holding (MDIA) +63%.iTeos Therapeutics (ITOS) +52%.Entasis Therapeutics Holdings (ETTX) +25%.Orphazyme A/S (ORPH) +23%.Luokung Technology (LKCO) +22%.Mereo BioPharma Group plc (MREO) +17...

Metacrine (MTCR) has completed enrollment for its Phase 2a trial evaluating MET409 in combination with empagliflozin (Jardiance), a sodium-glucose cotransport-2 ((SGLT2)) inhibitor, in patients with type 2 diabetes and non-alcoholic steatohepatitis ((NASH)).The company plans to report to...

Topline data expected to be reported in the fourth quarter of 2021 SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, to...

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive off...